Christmas Island

Reimbursed Care Access

Christmas Island is an Australian external territory and is subject to Australian Commonwealth drug and therapeutic regulation. Federal scheduling and Therapeutic Goods Administration (TGA) frameworks that govern medical access, importation and reimbursement on the Australian mainland also apply to Christmas Island, so psychedelics follow the same constrained medical-access pathways or prohibited (Schedule 9) status used nationally. Clinical‑trial access is possible under research licences, while authorised psychiatric prescribing pathways govern limited therapeutic use for psilocybin and MDMA; esketamine (Spravato) is TGA‑approved and (from 1 May 2025) listed on the Pharmaceutical Benefits Scheme (PBS) with authority controls.